FDA Accepts Application for SARCLISA (Isatuximab-IRFC) by Sanofi
The FDA has accepted the Biologics License Application for SARCLISA (Isatuximab-IRFC) from Sanofi.
Asset / Drug
Drug and asset intelligence for SARCLISA with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.